home / stock / gild / gild articles

GILD Articles, Gilead Sciences Inc. - From 12/21/23

Stock Information
Company Name: Gilead Sciences Inc.
Stock Symbol: GILD
Market: NASDAQ
Website: gilead.com
Menu
GILD GILD Quote GILD Short GILD News GILD Articles GILD Message Board
Get GILD Alerts

News, Short Squeeze, Breakout and More Instantly...
Why Is Immunotherapy-Focused Hookipa Pharma Stock Soaring Today? | Benzinga

Gilead Sciences Inc (NASDAQ: GILD) announced on Thursday that it has purchased 15 million shares of HOOKIPA Pharma Inc (NASDAQ: HOOK...
RedHill's Investigational COVID-19 Drugs Combined With Gilead's Show Effect Against Ebola | Benzinga

RedHill Biopharma Ltd (NASDAQ: RDHL) says opaganib and RHB-107 (upamostat) demonstrated robust synergistic effects when combined individually ...

Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today? | Benzinga

Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody prog...

Gilead Sciences Battles Rising Threat of Drug Counterfeiting, Initiates Legal Actions | Benzinga

Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health ...
A Look Into Gilead Sciences Inc's Price Over Earnings | Benzinga

Looking into the current session, Gilead Sciences Inc. (NASDAQ:GILD) shares are trading at $79.44, after a 0.10% increase. Moreover, over the past ...

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $11,000 Today | Benzinga

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 5.36% on an annualized basis producing an average annual return...

Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies | Benzinga

Tuesday, the FDA said it received reports of patients developing T-cell malignancies, including chimeric antigen receptor CAR-positive ly...
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,000 Today | Benzinga

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 4.81% on an annualized basis producing an average annual return...

FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug | Benzinga

FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of ad...

Gilead Sciences Stock Slides After Hours On Q3 Report - Here's Why | Benzinga

Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's after-hours session on the heels of the company's third-qua...
Previous 10 Next 10